HUTCHMED (China) Limited (AIM:HCM)
157.50
+1.50 (0.96%)
Jun 17, 2026, 4:05 PM GMT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,796 employees as of December 31, 2025. The number of employees decreased by 15 or -0.83% compared to the previous year.
Employees
1,796
Change (1Y)
-15
Growth (1Y)
-0.83%
Revenue / Employee
226.92K GBP
Profits / Employee
189.02K GBP
Market Cap
1.34B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,535 |
| Hikma Pharmaceuticals | 9,400 |
| Allergy Therapeutics | 584 |
| ECO Animal Health Group | 200 |
| Shield Therapeutics | 63 |
| Venture Life Group | 43 |
| Chill Brands Group | 11 |
| Provexis | 2 |
HUTCHMED (China) News
- 21 hours ago - HUTCHMED (China) Ltd (HCM) Shares Fall 3.5% -- What GF Score of 81 Tells Investors - GuruFocus
- 1 day ago - Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PRNewsWire
- 1 day ago - isolved Honors Top-Performing Partners at Annual Connect for Partners Event - GlobeNewsWire
- 2 days ago - isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees - GlobeNewsWire
- 2 days ago - Paychex Recognized as a Top WorkTech Company by TIME - GlobeNewsWire
- 5 days ago - HUTCHMED's Sovleplenib Meets Phase III Goal In WAIHA, Showing 66% Durable Response Rate; Stock Up - Nasdaq
- 5 days ago - HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress - GlobeNewsWire
- 19 days ago - A Look at HUTCHMED (China) Ltd (HCM) After 4.3% Decline -- GF Value $13.82 vs Price $11.22 - GuruFocus